Cleerly
Cleerly to Present Innovative Research on Age and Sex-Specific Coronary Artery Disease at AHA Scientific Sessions 2024
New Insights from AI-Quantitative Coronary CT (AI-QCT) Data to be Shared in Chicago, November 16-18, 2024
Heart Health Innovator Cleerly Closes Series C Funding Round with $223 Million
High-profile investors led by T. Rowe Price and Fidelity back a new standard of care for cardiovascular disease
This press release was updated on July 28, 2022 to reflect that Cleerly secured additional Series C funding, raising its round total from $192 million to $223 million.
Updated July 28, 2022: New York – July 25, 2022 -- Cleerly, the company creating a new standard of care for heart disease, announced that it has closed a Series C financing round of $223 million. This new funding brings the total raised by the fast-growing health care company to $279 million, which includes its Series B round in 2021.
“At Cleerly, we are passionate about our mission to create a new standard of care for heart disease,” said James Min, MD, FACC, FESC, MSCCT, CEO and founder of Cleerly. “We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care. The status quo for heart health simply isn’t good enough – for patients, providers, or payors – and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now.”
The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company. They are joined by additional investors spanning the health care, pharmaceutical and technology sectors, including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis and Pura Vida Investments. Cleerly’s existing investors also participated in the financing and include Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
Cleerly’s AI-enabled approach to evaluating coronary computed tomography (CT) angiograms allows physicians to more easily identify, characterize and qualify atherosclerosis (plaque) buildup in the walls of the heart arteries. This information promotes a more accurate understanding of a patient’s risk of heart attack and represents a marked shift from the way that heart disease has been historically assessed using indirect surrogate markers of disease. These surrogates too often fail patients as predictors and miss the majority of patients who will suffer a heart attack. In fact, more than half of all patients who experience a heart attack show no symptoms before their potentially catastrophic event. When patients do present with symptoms of a cardiac event, Cleerly offers support to physicians that improves diagnostic certainty to personalize therapeutic choices that offer clinical benefit and reduce total costs of care.
This funding round will enable Cleerly to expand its team as well as extend its commercial reach to broaden patient and physician access to its comprehensive technology-enabled care pathway across the entire continuum of disease presentation—from early diagnosis of heart disease to ensuring that ongoing treatments are effective for those who have that elevated risk or symptoms. In addition, the company will invest in additional large-scale outcomes research to establish it as the standard of care supporting physicians through personalized evaluation and treatment of heart disease. Cleerly has more than a dozen ongoing multicenter clinical trials, including an international registry enrolling more than 100,000 patients over the next decade – making it the largest cardiovascular phenotype outcomes study ever performed.
About Cleerly
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.
Cleerly Press Contact:
Resources
Cleerly Presents Late-Breaking Research on AI-Enabled Quantitative CT Coronary Assessment for Predicting Major Adverse Cardiovascular Events at TCT 2024
Part of the multicenter international CONFIRM2 Registry, the study found key metrics to predict cardiac events
Cleerly Secures CPT® Category I Code for AI-QCT Advanced Plaque Analyses
After Five Years of Collaboration, Cleerly’s Innovative Technology Gains Permanent Recognition
Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based Care
Cleerly : August 15, 2022
Heart Health Innovator Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based CareHire follows Cleerly's $223 million Series C and furthers...
Cleerly's Proxy solution improves heart disease imaging workflows
Cleerly : October 31, 2022
Cleerly introduces Proxy solution to improve heart disease imaging workflowsProxy allows for seamless data transmission and improved AI-based plaque...
Cleerly joins AHA Center for Health Technology & Innovation Innovators’ Network
Cleerly : October 24, 2023
Cleerly joins American Heart Association Center for Health Technology & Innovation Innovators’ NetworkAmerican Heart Association consortium advances...